| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
7 analysts have expressed a variety of opinions on AbbVie (NYSE:ABBV) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 6 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
Analysts have recently evaluated AbbVie and provided 12-month price targets. The average target is $190.29, accompanied by a high estimate of $200.00 and a low estimate of $180.00. Observing a downward trend, the current average is 1.4% lower than the prior average price target of $193.00.
A clear picture of AbbVie's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Christopher Raymond | Piper Sandler | Maintains | Overweight | $190.00 | $190.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $200.00 | $200.00 |
| Christopher Raymond | Piper Sandler | Raises | Overweight | $190.00 | $185.00 |
| Rajesh Kumar | HSBC | Announces | Buy | $185.00 | - |
| Louise Chen | Cantor Fitzgerald | Announces | Overweight | $200.00 | - |
| Carter Gould | Barclays | Lowers | Overweight | $187.00 | $195.00 |
| Evan David Seigerman | BMO Capital | Lowers | Outperform | $180.00 | $195.00 |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of AbbVie's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on AbbVie analyst ratings.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, AbbVie showcased positive performance, achieving a revenue growth rate of 0.7% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: AbbVie's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.04%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 14.8%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): AbbVie's ROA stands out, surpassing industry averages. With an impressive ROA of 0.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 9.24, AbbVie faces challenges in effectively managing its debt levels, indicating potential financial strain.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ABBV
